Caris Life Sciences, Inc. (CAI) Income Statement
CAI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCAI revenue and net income
Where CAI's revenue goes
2025Each bar shows an amount and its share of revenue. CAI kept −66.2% of revenue as net income.
CAI profit margins
CAI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +97.0% | +46.5% | +14.3% | +13.6% |
| Gross profit | +201.6% | +88.9% | +21.9% | +13.7% |
| Operating income | — | — | −19.1% | −7.4% |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CAI quarterly EPS vs estimates
Caris Life Sciences beat the analyst EPS estimate in 3 of the last 6 quarters. Next report: November 4, 2026 (estimate $0.03).
CAI income statement
| 2025 | 2024 | 2023 | 2022 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $812.0M | $412.3M | $306.1M | $258.5M | $294.0M | $416.5M | $432.1M | $348.4M | $294.4M | $249.7M |
| Cost of revenue | $272.9M | $233.5M | $216.8M | $178.5M | $109.9M | $216.0M | $218.5M | $179.1M | $156.9M | $123.8M |
| Gross profit | $539.2M | $178.8M | $89.3M | $80.0M | $184.2M | $200.5M | $213.6M | $169.3M | $137.5M | $125.9M |
| Research & development | $45.3M | $113.9M | $116.9M | $101.3M | — | — | — | — | — | — |
| Sales, general & admin | $392.5M | $321.9M | $291.5M | $294.5M | $27.3M | $52.7M | $50.3M | $42.7M | $35.7M | $27.6M |
| Total operating expenses | $494.1M | $435.9M | $408.9M | $395.8M | $45.1M | $70.2M | $64.8M | $63.6M | $71.5M | $57.8M |
| Operating income | $45.1M | −$257.1M | −$319.6M | −$315.8M | $139.1M | $130.3M | $148.8M | $105.7M | $66.0M | $68.1M |
| Interest income | $16.5M | $7.1M | $11.3M | $947,000 | — | — | — | — | — | — |
| Interest expense | $56.9M | $50.0M | $31.6M | $26.7M | $61.6M | $79.2M | $78.3M | $53.1M | $42.8M | $36.0M |
| Income before taxes | −$68.1M | −$281.9M | −$341.4M | −$320.8M | $29.5M | $55.2M | $81.5M | $57.2M | $9.9M | $31.2M |
| Income taxes | $469.9M | — | — | — | $1.8M | $4.2M | $2.9M | −$14.9M | $3.8M | $4.3M |
| Net income | −$538.0M | −$281.9M | −$341.4M | −$320.8M | $27.7M | $31.0M | $78.6M | $72.1M | $6.0M | $26.8M |
| EBITDA | $11.4M | −$183.0M | −$260.8M | −$245.9M | $254.5M | $248.3M | $283.3M | $223.5M | $159.3M | $181.4M |
| EPS (diluted) | −$1.10 | −$1.00 | — | — | $1.55 | $1.78 | $4.07 | $3.58 | $0.31 | $1.32 |
| Gross margin | 66.4% | 43.4% | 29.2% | 31.0% | 62.6% | 48.1% | 49.4% | 48.6% | 46.7% | 50.4% |
| Operating margin | 5.6% | −62.4% | −104.4% | −122.2% | 47.3% | 31.3% | 34.4% | 30.3% | 22.4% | 27.3% |
| Net margin | −66.2% | −68.4% | −111.5% | −124.1% | 9.4% | 7.4% | 18.2% | 20.7% | 2.0% | 10.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Sep '21 | Jun '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $263.7M | $216.2M | $292.9M | $216.8M | $181.4M | $120.9M | $129.9M | $101.6M | $100.0M | $80.7M | $100.8M | $85.7M |
| Cost of revenue | $84.1M | $74.8M | $72.0M | $69.3M | $67.7M | $63.9M | $59.2M | $57.2M | $62.5M | $54.6M | $46.7M | $42.8M |
| Gross profit | $179.6M | $141.3M | $220.9M | $147.5M | $113.7M | $57.1M | $70.7M | $44.4M | $37.6M | $26.1M | $54.1M | $85.7M |
| Research & development | $32.4M | $5.4M | $31.8M | $21.6M | $25.0M | $23.1M | $27.1M | $27.6M | $24.8M | $34.4M | — | — |
| Sales, general & admin | $120.3M | $104.8M | $100.7M | $93.2M | $64.4M | $91.9M | $73.9M | $77.6M | $41.1M | $84.0M | $12.3M | $10.2M |
| Total operating expenses | $152.7M | $136.1M | $132.5M | $114.9M | $95.7M | $115.0M | $107.7M | $105.3M | −$29.5M | $118.3M | $12.3M | $34.9M |
| Operating income | $26.9M | $5.3M | $88.4M | $32.6M | $18.0M | −$58.0M | −$37.0M | −$60.8M | $67.0M | −$92.2M | $66.4M | $50.8M |
| Interest income | $6.8M | $6.8M | $7.0M | $7.4M | $1.6M | $503,000 | — | — | $2.6M | $1.8M | — | — |
| Interest expense | $9.2M | $12.8M | $11.4M | $13.5M | $19.2M | $12.8M | $13.3M | $13.8M | $13.7M | $9.3M | — | $11.1M |
| Income before taxes | −$614,000 | −$644,000 | $82.0M | $24.3M | −$71.8M | −$102.6M | −$36.9M | −$67.7M | −$66.2M | −$111.0M | $54.8M | $39.8M |
| Income taxes | $23,000 | −$134,000 | — | — | — | — | — | — | — | — | $3.7M | $1.9M |
| Net income | −$637,000 | −$510,000 | $82.0M | $24.3M | −$71.8M | −$102.6M | −$36.9M | −$67.7M | −$66.2M | −$111.0M | $51.2M | $37.9M |
| EBITDA | $15.2M | $17.2M | $97.6M | $42.7M | −$46.2M | −$82.8M | −$28.0M | −$50.3M | −$40.9M | −$84.0M | $87.7M | $50.9M |
| EPS (diluted) | −$0.54 | −$0.00 | $0.28 | $0.08 | −$1.11 | −$0.35 | — | — | — | — | — | — |
| Gross margin | 68.1% | 65.4% | 75.4% | 68.0% | 62.7% | 47.2% | 54.4% | 43.7% | 37.5% | 32.4% | 53.6% | 100.0% |
| Operating margin | 10.2% | 2.4% | 30.2% | 15.1% | 9.9% | −47.9% | −28.5% | −59.9% | 67.0% | −114.3% | 65.9% | 59.3% |
| Net margin | −0.2% | −0.2% | 28.0% | 11.2% | −39.6% | −84.8% | −28.4% | −66.6% | −66.2% | −137.6% | 50.7% | 44.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CAI's financial statements (latest annual report filed March 3, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CAI financial results
In fiscal year 2025 (ended December 31, 2025), Caris Life Sciences reported revenue of $812.0 million, up 97.0% from the year before. It had a net loss of $538.0 million, a net profit margin of −66.2%. Diluted earnings per share came to −$1.10. Over five years revenue grew at an average rate of 14.3% a year.
See the CAI stock overview for the latest quote and news, or the CAI chart for price history and technical indicators.
CAI income statement FAQ
What is Caris Life Sciences's annual revenue?
Caris Life Sciences reported total revenue of $812.0 million for fiscal year 2025, which ended on December 31, 2025. That was up 97.0% from $412.3 million the previous year.
Is Caris Life Sciences profitable?
No. Caris Life Sciences reported a net loss of $538.0 million in fiscal 2025, a net profit margin of −66.2%; its operating margin was 5.6%.
What is Caris Life Sciences's gross margin?
Caris Life Sciences's gross margin was 66.4% in fiscal 2025: for every $100 of revenue, Caris Life Sciences kept $66 after the direct cost of its products and services.
How much does Caris Life Sciences spend on research and development?
Caris Life Sciences spent $45.3 million on research and development in fiscal 2025, 5.6% of revenue.
How fast is Caris Life Sciences growing?
Revenue grew 14.3% a year on average over the last five fiscal years, from $416.5 million to $812.0 million.
What are Caris Life Sciences's earnings per share?
Caris Life Sciences earned $-1.10 per diluted share in fiscal 2025, compared with $-1.00 a year earlier.
When will Caris Life Sciences report its next earnings?
Caris Life Sciences is expected to report results for the quarter ending September 30, 2026 on November 4, 2026 after the market closes.
When does Caris Life Sciences's fiscal year end?
Caris Life Sciences's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 3, 2026.